Toxic Effects of Zidovudine in Asymptomatic Human Immunodeficiency Virus-Infected Individuals With CD4+ Cell Counts of 0.50×109/L or Less: Detailed and Updated Results From Protocol 019 of the AIDS Clinical Trials Group

Archives of Internal Medicine

Volumn 152, Issue 11, 1992, Pages 2286-2292

  Koch, Matthew A ^a   Volberding, Paul A ^b   Lagakos, Stephen W ^c   Booth, David K ^a   Pettinelli, Carla ^d   Myers, Maureen W ^d,e  

^a RTI INTERNATIONAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CD4 ANTIGEN; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; FEMALE; HELPER CELL; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LEUKOCYTE DIFFERENTIAL COUNT; LIVER DYSFUNCTION; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOMITING;

ANEMIA; CD4-POSITIVE T-LYMPHOCYTES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV SEROPOSITIVITY; HUMAN; MALE; NEUTROPENIA; RISK FACTORS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; THROMBOCYTOPENIA; ZIDOVUDINE;

EID: 0026490091     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.1992.00400230094016     Document Type: Article

References (18)

1. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med. 1987;317:192-197.
2. Richman DD, Andrews JA, AZT Collaborative Working Group. Results of continued monitoring of participants in the placebo-controlled trial of zidovudine for serious human immunodeficiency virus infection. Am J Med. 1988;85(suppl 2A):208-213.
3. Dournon E, Matheron S, Rozenbaum W, et al. Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex. Lancet. 1988;2:1297-1302.
4. Smiley L, AZT Collaborative Group. Zidovudine treatment of patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex: long-term experience. J Infect. 1989;18 (suppl 1):77.
5. Fischl MA, Richman DD, Causey DM, et al. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. JAMA. 1989;262:2405-2410.
6. Williams I, Gabriel G, Cohen H, et al. Zidovudine—the first year of experience. J Infect. 1989;18(suppl 1):23-31.
7. Pinching AJ, Helbert M, Peddle B, et al. Clinical experience with zidovudine for patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex. J Infect. 1989;18 (suppl 1):33-40.
8. Stambuk D, Hawkins D, Gazzard BG. Zidovudine treatment of patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex: St Stephen’s Hospital experience. J Infect. 1989;18(suppl 1):41-51.
9. Fischl MA, Parker CB, Pettinelli C, et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1990;323:1009-1014.
10. Gelmon K, Montaner JSG, Fanning M, et al. Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial. AIDS. 1989;3:555-561.
11. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection: a double-blind, placebocontrolled trial. Ann Intern Med. 1990;112:727-737.
12. Hamilton JD, Hartigan PM, Simberkoff MS, et al. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection: results of the Veterans Affairs cooperative study. N Engl J Med. 1992;326:437-443.
13. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med. 1990;322:941-949.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
15. Cox DR. Regression models and life-tables. J R Stat Soc B. 1972;34:187-220.
16. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons Inc; 1980.
17. Food and Drug Administration. ‘COSTART,’ Coding Symbols for Thesaurus of Adverse Reaction Terms. 2nd ed. Rockville, Md: Dept of Health and Human Services; 1985.
18. Fleiss, DL. Statistical Methods for Rates and Proportions. New York, NY: John Wiley & Sons Inc; 1981.